Shock Therapeutics Biotech
STBI is an early-stage biopharmaceutical company founded to advance the development of a revolutionary medical discovery that could reverse the condition of shock, buying time for life-saving critical care interventions.
Hypovolemic Shock (Hemorrhagic Shock or Shock) is the condition which precedes death in almost all cases of fatal injury & trauma.
Leading cause of death under 45 annually killing
Annually injury and violence kill an estimated
Leading cause of potentially
Eastridge & Holcomb 2019
Unfortunately, once shock sets in, it is incredibly hard to reverse. We believe this is because the current treatment options are for the trauma and symptoms of shock - not for shock itself.